Published in:
Open Access 01-12-2018 | Correction
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
Published in: Radiation Oncology | Issue 1/2018
Login to get accessExcerpt
Following the publication of this article [1], the authors noticed that Figs. 2, 3, 4 and 5 were in the incorrect order and thus had incorrect captions.
Fig. 2
Representative example of imaging modalities MRI T1, T2*, and FMISO-PET. Primary tumour and lymph node metastasis (pt. 5, tonsillar carcinoma) at week 0, 2, and 5 (upper, middle, lower panel): co-registered image sets from MRI T1, MRI T2*, FMISO-PET (left to right). Red contours: GTV-T, GTV-LN. Blue contour: HSV-LN
Fig. 3
Time course of T2* values within volumes. T2* mean ± STD within tumour, lymph nodes and normal tissue for all patients (n = 10)
Fig. 4
Hypoxic tumour subvolumes: T2* values vs. FDG uptake and FMISO uptake. T2* values (ms) were lower and FDG uptake was higher within hypoxic tumour subvolumes as compared to non-hypoxic tumour subvolumes (*p = 0.051, **p = 0.026). FMISO uptake was higher within hypoxic tumour subvolumes than within non-hypoxic tumour subvolumes (***p = 0.029, p = 0.072, ****p = 0.003, p = 0.0001)
Fig. 5
Correlation of FMISO uptake with mean T2* and FDG uptake. Plots showing correlation within GTV-T at baseline
× ![]()
× ![]()
× ![]()
× ![]()
…